65,437 trials
Diabetes
Primary: Change From Baseline in Hemoglobin A1 (A1C) at Week 24 — 8.04; 7.93; 8.02; 7.79 percent
Diabetes Mellitus, Type 1
Primary: Change in Hemoglobin A1c (HbA1c) From Baseline to Endpoint — 8.88; 8.68; -0.69; -0.59 percent of HbA1c — p=0.332
Diabetes Mellitus, Non-Insulin-Dependent
Primary: Change From Baseline in HbA1c at Week 12 — -0.70; -0.30 Percent — p=<0.001
Diabetes Mellitus, Non-Insulin-Dependent
Primary: Change From Baseline in 24-hour Weighted Mean Plasma Glucose — -34.9; -28.6; -9.0 mg/dL — p=<0.001
Pharmacokinetics
Primary: Maximum Plasma Concentration (Cmax) — 2,172.96; 1,971.10 pg/mL
Healthy; Adult; Volunteer; Colchicine; Pharmacokinetics; Diltiazem; Cytochrome p450 3A4; P-glycoprotein
Primary: Maximum Plasma Concentration (Cmax) — 2,172.32; 2,802.90 pg/mL
Pharmacokinetics
Primary: Maximum Plasma Concentration (Cmax) — 2.84; 8.44 ng/mL
Hepatitis B
Primary: Hepatitis B Surface Antibody Seroprotective Rate(Seroprotective: for Those Who Had Anti-HBs(Surface Antibody Against Hepatitis B) Titer Higher Than 10 mIU/mL) — 26; 96…
Pharmacokinetics
Primary: Maximum Plasma Concentration (Cmax) — 2,968.42; 3,850.63 pg/mL
HIV Infection · Infection, Human Immunodeficiency Virus
Primary: Percentage of Participants Not Meeting the Definition of Virologic Failure at or Prior to Week 24 — 92.1; 94.2 Percentage of participants
Parkinson Disease · Depression
Primary: Change From Baseline in the Beck Depression Inventory-Version 1A (BDI-IA) Total Score at Week 12 — -4; -5.9 Score on scale — p=0.0103
Pharmacokinetics
Primary: Maximum Plasma Concentration (Cmax) — 1,869.50; 4,993.06 pg/mL
Osteoporosis
Primary: Plasma C-terminal Telopeptide of Type I Collagen (CTx-1)(% Change From Baseline) — -74.17; -71.99; -68.40 % Change in Baseline CTx-1
Pharmacokinetics
Primary: Maximum Plasma Concentration (Cmax) — 2,779.08; 5,266.92 pg/mL
Pharmacokinetics · Healthy
Primary: Maximum Plasma Concentration (Cmax) — 2,720.04; 8,817.48 pg/mL